ADAC Laboratories has forged an exclusive vendor agreement with PET radiopharmaceutical manufacturer Eastern Isotopes. The partnership gives ADAC access to 5.5 millicurie doses of FDG, which it will buy at a discount from Eastern Isotopes, and allows it
ADAC Laboratories has forged an exclusive vendor agreement with PET radiopharmaceutical manufacturer Eastern Isotopes. The partnership gives ADAC access to 5.5 millicurie doses of FDG, which it will buy at a discount from Eastern Isotopes, and allows it to supply its molecular coincidence detection/attenuation correction (MCD/AC) and CPET customers. ADACs FDG imaging products do not require 10 millicurie doses of the radioisotope, as competitive products do, according to the Milpitas, CA, company.
Based in Sterling, VA, Eastern Isotopes was established in 1995 as a distributor of SPECT pharmaceuticals. Last year, the firm began to produce high-energy tracers, particularly FDG, for therapy, oncology, cardiology, and neurology.
With the deal, ADAC continues its push into the PET market, capitalizing on the momentum created by its September purchase of partner UGM Medical, a developer and manufacturer of PET devices (SCAN 9/29/99). The two firms codeveloped ADACs MCD high-energy imaging option for gamma cameras (SCAN 12/14/94).
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.